JJ&K Pharma LTD
Your Global Partner in Life-Saving Medications
产品
| Time | Listing plan for raw materials |
制剂注册文号 |
制剂上市销售 |
销售额（亿） |
|
2022 |
实现肝素钠和依诺肝素钠原料药上市 |
10 |
||
|
2023 |
那曲和达特原料药注册申报 |
肝素钠2个品规注射剂注册申报 |
12 |
|
|
2024 |
舒洛地特和喜辽妥原料药注册申报 |
依诺那曲达特预灌针注册申报 |
14.4 |
|
|
2025 |
贝米肝素原料药注册申报 |
喜辽妥软膏注册申报 |
肝素注射液上市销售 |
17.3 |
|
2026 |
磷脂原料药注册申报 （已获市科委资金支持） |
舒洛地特注射液及软胶囊注册申报 |
依诺肝素预灌针上市销售 |
20.7 |
|
2027 |
口服固体制剂（达群）注册申报 |
那曲达特预灌针上市销售 |
25.9 |
|
|
2028 |
寡核苷酸原料药注册申报 （已获市科委资金支持） |
阿班与利班固体制剂注册申报，磷脂注射剂注册申报 |
喜辽妥软膏上市销售 |
32.4 |
|
2029 |
贝米肝素注射液注册申报，氯比固体制剂注册申报 |
舒洛地特注射剂及软胶囊制剂上市销售 |
36.0 |
|
|
2030 |
阿加曲班原料药注册上市 |
达群片剂和磷脂注射液上市销售 |
40.0 |
|
|
2031 |
厄贝沙班氢氯噻嗪片剂注册申报 |
阿班和利班片剂及寡核苷酸注射液上市 |
44.4 |
QUALITY
With applications in major surgeries and life-critical conditions, ensuring the quality and efficacy of our products is paramount to safeguarding patient health.
From raw material sourcing to final product distribution, our rigorous quality management system ensures that every product meets stringent regulatory standards. Each batch at every stage of production is analyzed and documented by experienced production and quality engineers who undergo regular GMP training.
Through our unwavering dedication to quality, we aim to enhance the well-being of patients worldwide.
INNOVATION
Our R&D team is composed of innovative and highly skilled professionals dedicated to advancing our product offerings. They are constantly exploring new technologies, methodologies, and scientific discoveries to drive innovation and maintain our competitive edge. Their expertise spans multiple disciplines, allowing for a comprehensive approach to research and development.
Through rigorous testing and continuous improvement, our team ensures that our solutions meet the highest standards of quality and efficacy
